[go: up one dir, main page]

WO2024175802A3 - Anticorps neutralisant le sars-cov-2 - Google Patents

Anticorps neutralisant le sars-cov-2 Download PDF

Info

Publication number
WO2024175802A3
WO2024175802A3 PCT/EP2024/054717 EP2024054717W WO2024175802A3 WO 2024175802 A3 WO2024175802 A3 WO 2024175802A3 EP 2024054717 W EP2024054717 W EP 2024054717W WO 2024175802 A3 WO2024175802 A3 WO 2024175802A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antigen
binding fragments
sars
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/054717
Other languages
English (en)
Other versions
WO2024175802A2 (fr
Inventor
Florian Klein
Timm WEBER
Sabrina DÄHLING
Svea ROSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet zu Koeln
Original Assignee
Universitaet zu Koeln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet zu Koeln filed Critical Universitaet zu Koeln
Publication of WO2024175802A2 publication Critical patent/WO2024175802A2/fr
Publication of WO2024175802A3 publication Critical patent/WO2024175802A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci contre le coronavirus associé au SARS, des compositions pharmaceutiques comprenant de tels anticorps ou des fragments de liaison à l'antigène de ceux-ci, des kits comprenant de tels anticorps ou fragments de liaison à l'antigène de ceux-ci, et les anticorps ou fragments de liaison à l'antigène de ceux-ci, les compositions pharmaceutiques et les kits pour une utilisation en tant que médicament, et dans le traitement ou la prévention d'une maladie provoquée par le coronavirus associé au SARS. La présente invention concerne en outre des procédés de traitement, de prévention ou de réduction de la gravité d'une infection par un coronavirus associé au SARS, et des acides nucléiques codant pour de tels anticorps ou fragments de liaison à l'antigène de ceux-ci, des vecteurs d'expression comprenant de tels acides nucléiques, des cellules hôtes comprenant de tels acides nucléiques ou vecteurs d'expression, et des procédés de production de tels anticorps ou fragments de liaison à l'antigène de ceux-ci.
PCT/EP2024/054717 2023-02-24 2024-02-23 Anticorps neutralisant le sars-cov-2 Ceased WO2024175802A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23158651.2 2023-02-24
EP23158651 2023-02-24

Publications (2)

Publication Number Publication Date
WO2024175802A2 WO2024175802A2 (fr) 2024-08-29
WO2024175802A3 true WO2024175802A3 (fr) 2024-10-17

Family

ID=85384409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/054717 Ceased WO2024175802A2 (fr) 2023-02-24 2024-02-23 Anticorps neutralisant le sars-cov-2

Country Status (2)

Country Link
TW (1) TW202440626A (fr)
WO (1) WO2024175802A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022235867A2 (fr) * 2021-05-06 2022-11-10 The Rockefeller University Anticorps neutralisant anti-sars-cov-2 et leurs procédés d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0885002B1 (fr) 1996-03-04 2011-05-11 The Penn State Research Foundation Materiaux et procedes permettant d'accroitre la penetration intracellulaire
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0954282B1 (fr) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation de particules pour inhalation
WO1998049198A1 (fr) 1997-04-30 1998-11-05 Enzon, Inc. Proteines a chaine unique fixant les antigenes capables de glycosylation, production et utilisations de ces dernieres
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (fr) 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022235867A2 (fr) * 2021-05-06 2022-11-10 The Rockefeller University Anticorps neutralisant anti-sars-cov-2 et leurs procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAO YUNLONG ET AL: "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 1, 9 July 2020 (2020-07-09), pages 73 - 84, 16, XP086211425, ISSN: 0092-8674, [retrieved on 20200518], DOI: 10.1016/J.CELL.2020.05.025 *
CHEN YANJIA ET AL: "Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses", vol. 23, no. 3, 27 September 2022 (2022-09-27), London, pages 189 - 199, XP093063418, ISSN: 1474-1733, Retrieved from the Internet <URL:https://www.nature.com/articles/s41577-022-00784-3> DOI: 10.1038/s41577-022-00784-3 *
LUO SAI ET AL: "An Antibody from Single Human V H -rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion", 11 August 2022 (2022-08-11), US, XP055958420, ISSN: 2470-9468, Retrieved from the Internet <URL:http://dx.doi.org/10.1126/sciimmunol.add5446> DOI: 10.1126/sciimmunol.add5446 *

Also Published As

Publication number Publication date
TW202440626A (zh) 2024-10-16
WO2024175802A2 (fr) 2024-08-29

Similar Documents

Publication Publication Date Title
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
WO2019193183A3 (fr) Nouvelles molécules d&#39;acide nucléique de fièvre jaune pour la vaccination
WO2021191630A8 (fr) Vaccin contre un coronavirus
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D&#39;UTILISATION DE CEUX-CI
WO2021239935A9 (fr) Anticorps neutralisants contre le coronavirus associé au sars
WO2022192594A3 (fr) Molécules d&#39;acide nucléique et vaccins les comprenant pour la prévention et le traitement d&#39;infections à coronavirus et de maladie
WO2024175802A3 (fr) Anticorps neutralisant le sars-cov-2
WO2020104943A3 (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2022197720A3 (fr) Compositions et méthodes de traitement d&#39;une infection à coronavirus
WO2023242817A3 (fr) Molécules d&#39;arn recombinant comprenant des régions ou des segments non traduits codant pour une protéine de spicule à partir de la souche omicron de coronavirus 2 du syndrome respiratoire aigu sévère
WO2022047128A3 (fr) Procédé de traitement de troubles médiés par le complément provoqués par des bétacoronavirus
MX2025002405A (es) Composiciones farmaceuticas contra el virus del herpes
BR112022015361A2 (pt) Composição farmacêutica para prevenir ou tratar doenças pulmonares, composição de alimentos funcionais para a saúde para melhorar ou prevenir doenças pulmonares e método de prevenção ou tratamento de doenças pulmonares em um indivíduo em necessidade do mesmo
WO2022011110A3 (fr) Compositions et méthodes de diagnostic et de traitement de l&#39;infection par le virus sars-cov-2
WO2022150654A3 (fr) Polypeptides de liaison à l&#39;antigène spécifiques aux coronavirus et leurs utilisations
WO2023230348A3 (fr) Régimes posologiques pour le traitement d&#39;une infection par la dengue
WO2025003275A3 (fr) Anticorps neutralisant le cytomégalovirus humain
WO2022011271A3 (fr) Probiotiques destinés à être utilisés dans la prévention ou le traitement de maladies et/ou de symptômes associés à des coronavirus
BR0314986A (pt) Sequência de polinucleotìdeo, vetor de expressão, composição farmacêutica, usos de uma sequência de polinucleotìdeo, de um vetor e de uma composição, e, método para tratar ou prevenir infecções pelo hpv ou qualquer sintomas ou doenças associados com elas
IL314179A (en) Compositions and methods for the treatment of depression
WO2021207716A3 (fr) Méthodes et composition pour le traitement de la maladie covid-19 nécessitant une hospitalisation
WO2022235867A3 (fr) Anticorps neutralisant anti-sars-cov-2 et leurs procédés d&#39;utilisation
AR133129A1 (es) Anticuerpos monoclonales humanos neutralizantes contra p. aeruginosa
WO2024182666A3 (fr) Procédés de ciblage et de traitement de maladies associées à samd9 ou samd9l
WO2021209493A3 (fr) Moyens et procédés de prévention et de traitement d&#39;infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24706463

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024706463

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024706463

Country of ref document: EP

Effective date: 20250924

ENP Entry into the national phase

Ref document number: 2024706463

Country of ref document: EP

Effective date: 20250924